Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001179110-21-008086)

Filing Details

Accession Number:: 0001179110-21-008086
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-08-10 16:33:46
Reporting Period:: 2021-08-09

Accepted Time:: 2021-08-10 16:33:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650664	Editas Medicine Inc.	EDIT	Biological Products, (No Disgnostic Substances) (2836)	464097528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1755098	Michelle Robertson	C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-08-09	2,500	$30.65	31,235	No	4	M	Direct
Common Stock	Disposition	2021-08-09	2,500	$60.00	28,735	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-08-09	2,500	$0.00	2,500	$30.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
115,000		2030-01-08	No	4	M	Direct

Footnotes

The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2021.
This option was granted on January 9, 2020 and is scheduled to vest over four years, with 25% of the shares having vested on January 9, 2021, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 9, 2024.